Who are Both deferoxamine mesylate and colchicine's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/both-deferoxamine-mesylate-and-colchicine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Both deferoxamine mesylate and colchicine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Both deferoxamine mesylate and colchicine (Both deferoxamine mesylate and colchicine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Iron chelator + anti-inflammatory combination. Area: Cardiovascular.

phase 3 Iron chelator + anti-inflammatory combination Labile iron (deferoxamine); microtubule polymerization and NLRP3 inflammasome (colchicine) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Both deferoxamine mesylate and colchicine (Both deferoxamine mesylate and colchicine) — The George Institute. This combination uses deferoxamine to chelate iron and reduce oxidative stress, while colchicine suppresses inflammatory responses, together targeting myocardial injury and fibrosis in heart failure.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Both deferoxamine mesylate and colchicine TARGET	Both deferoxamine mesylate and colchicine	The George Institute	phase 3	Iron chelator + anti-inflammatory combination	Labile iron (deferoxamine); microtubule polymerization and NLRP3 inflammasome (colchicine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Iron chelator + anti-inflammatory combination class)

The George Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Both deferoxamine mesylate and colchicine — Competitive Intelligence Brief. https://druglandscape.com/ci/both-deferoxamine-mesylate-and-colchicine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab